World Conference on Lung Cancer

New trial data shows ivonescimab combined with chemotherapy significantly improves progression-free survival in EGFR-mutated non-small cell lung cancer patients.

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Tarlatamab-dlle combined with anti-PD-L1 therapy shows remarkable survival rates and manageable safety in extensive-stage small cell lung cancer patients.

SHR-4849 shows promising efficacy and manageable safety in relapsed small cell lung cancer, highlighting its potential as a targeted treatment option.

New findings reveal zongertinib's effectiveness against brain metastases in HER2-mutant non–small cell lung cancer, offering hope for better treatment options.

New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion–mutated NSCLC, offering hope for patients.

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for heavily treated patients.

Firmonertinib shows significant antitumor activity in EGFR PACC-mutated NSCLC, with promising results in CNS penetration and manageable safety profiles.

Ifinatamab deruxtecan shows promising antitumor activity in extensive-stage small cell lung cancer, with high response rates and durable outcomes.

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.

Melina E. Marmarelis, MD, reports the safety and efficacy data from the phase 1 CHRYSALIS-2 trial.

Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.

An easy way to double survival for patients with lung cancer is by removing the barriers to screening.

Datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy showed promising efficacy and a manageable safety profile in advanced/metastatic non–small cell lung cancer without actionable genomic alterations.

Pembrolizumab and etoposide continues to demonstrate improvements in survival outcomes compared with placebo and etoposide in patients with previously untreated extensive stage-small cell lung cancer.

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.

The combination of temozolomide and nivolumab demonstrated promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

Patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy are in need of new treatment options and strategies, according to a retrospective analysis presented at the 2022 World Conference on Lung Cancer.

Following treatment osimertinib, EGFR C797X mutations are now the leading mechanism of acquired resistance, outpacing MET amplification.

Amivantamab in combination with lazertinib and chemotherapy combination demonstrated encouraging responses in EGFR-mutant non–small cell lung cancer.

Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.

Atezolizumab may lead to improved overall survival when compared with the best supportive care in patients with resected non–small cell lung cancer.

David S. Hong, MD, discusses the data supporting the use of larotrectinib for the treatment of TRK fusion-positive lung tumors. He also explains the difference between larotrectinib another FDA-approved TRK inhibitor, entrectinib.